Carfilzomib

Regorafenib, M-2, M-5, and elacridar were purchased from Toronto Research Chemicals (North York, ON). Ko143 was from Sigma-Aldrich (St. Louis, MO). Imatinib mesylate was from Focus Biomolecules (Plymouth Meeting, PA). Afatinib, bortezomib, cabozantinib, carfilzomib, dabrafenib, dacomitinib, dasatinib, lapatinib, lenvatinib, pazopanib, ponatinib, ruxolitinib, tofacitinib, trametinib, vandetanib, and vemurafenib were from AdooQ Bioscience (Irvine, CA). Sorafenib was from LKT Laboratories Inc. (St. Paul, MN). Sunitinib was from Synkinase Pty Ltd. (San Diego, CA). Crizotinib was from LC Laboratories Inc. (Woburn, MA). Gefitinib and erlotinib were from Cayman Chemical Company (Ann Arbor, MI). Nilotinib was from ChemScene, LLC (Monmouth Junction, NJ). All other chemicals and reagents were of analytical grade and were obtained from commercial sources.

Carfi lzomib and cisplatin were purchased from AdooQ Bio-Science (CA, USA) and dissolved in dimethyl sulfoxide (DMSO) (Pars Tous Biotechnology, Mashhad, Iran) and stored at -20 °C until further use. cisplatin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and freshly solubilized in predetermined amounts of phosphate buffer with a relatively acidic pH, and kept away from light. RNA extraction kit was obtained from RiboEx (GeneAll, Korea) and SYBR Green master mix and cDNA synthesis kits were procured from Ampliqon A/S (Odense M, Denmark) and CinaColon (Tehran, Iran), respectively. 3-(4,5-dimethylhiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Trypan blue and Trypsin-EDTA were all purchased from from INOCLON (G. Innovative Biotech Co (INOCLON), Iran).
The A2780s and A2780cp ovarian cancer cells were procured from Pasteur Institute of Iran (Tehran, Iran) and incubated in RPMI1640 (Gibco, Thermofi sher, USA) supplemented with 10 % inactivated fetal Bovine serum (Gibco, Thermofi sher, USA), 100 U/mL penicillin (Sigma-Aldrich, St. Louis, MO), 100 U/mL streptomycin (Sigma-Aldrich, St. Louis, MO) at 37 °C in 5 % CO 2 and 95 % humidity. The A2780cp cell line was treated with cisplatin (1 μM) up to three passages before conducting the following assays. Cells treated with DMSO (up to 2 %) were considered as control group.